COVID-19：Actemra和remdecivir联合测试：Roche于6月开始注册
COVID-19：
瑞士罗氏公司：
宣布开始使用以下药物的组合进行临床试验。
中外：抗体药物“ Actemra”，
Gilead Sciences，Inc。：“remdesibir”（日本产品名称，Bekleuri）
对于重症患者：
从6月开始，案件注册将在欧洲和美国开始。
它结合了Actemra的免疫抑制作用和remdesibir的抗病毒作用。
证实了将来重症患者的治疗效果是否会增强。
化学日报
https://www.chemicaldaily.co.jp/
Roche – Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
Roche is also close to completing enrolment of a global randomised, double-blind, placebo-controlled phase III clinical trial of Actemra®/RoActemra® (tocilizumab) in hospitalised patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer.
Basel, 28 May 2020 –
Roche
today announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA)
to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir,
versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia,
in collaboration with Gilead Sciences, Inc.